Compare Brigit Biofarmaka Teknologi Tbk. (OBAT) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brigit Biofarmaka Teknologi Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Brigit Biofarmaka Teknologi Tbk. trades at Rp240 (market cap 166.01B, 324K 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Brigit Biofarmaka Teknologi Tbk. is the larger of the two by market cap. Which is the better fit depends on your goals.
| OBAT | SCPI | |
|---|---|---|
Market Cap | 166.01B | 104.4B |
Volume | 324K | — |
Lot | 3.24K | — |
Turnover | 77.68M | — |
Average Price | 239.75 | — |
Value | 77.68M | — |
Indicative Equilibrium Price | 240 | — |
Indicative Equilibrium Volume | 1 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brigit Biofarmaka Teknologi Tbk.
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
